OmniAb is a company that provides pharmaceutical industry partners access to the most diverse antibody repertoires and cutting-edge screening technologies to enable discovery of next-generation therapeutics. They have a website at https://www.omniab.com/ where you can find more information about their products and services.
Location: United States, California, Emeryville
Employees: 51-200
Founded date: 2012
Investors 1
| Date | Name | Website |
| 20.05.2024 | Avista Cap... | avistacap.... |
Mentions in press and media 6
| Date | Title | Description |
| 25.04.2023 | Andrew Ng’s Landing AI makes it easier to create computer vision apps with Visual Prompting | Join top executives in San Francisco on July 11-12, to hear how leaders are integrating and optimizing AI investments for success. Learn More Landing AI, a company that provides enterprise-wide transformation programs and solutions for indu... |
| 22.02.2023 | Andrew Ng and Landing AI seek to democratize AI for all company sizes, drive wider industry adoption | Andrew Ng’s cloud-based platform for computer vision, Landing AI, is taking on the advent of artificial intelligence (AI) development among companies of all sizes with its latest offering, LandingLens. The solution promises to facilitate sw... |
| 02.11.2022 | OmniAb Announces Completion of Spin-Off and Business Combination | Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif. (November 1, 2022) – OmniAb, Inc. (NASDAQ: OABI) today announced the co... |
| 11.10.2022 | Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination | Extraordinary General Meeting of APAC Shareholders to Vote on Proposed Business Combination with OmniAb to be Held on October 24, 2022 NEW YORK (October 3, 2022) – Avista Public Acquisition Corp. II (NASDAQ: AHPA) (“APAC”) announced today ... |
| 29.03.2022 | Ligand To Spin-Off Its OmniAb Business Through Merger With Avista Public Acquisition Corp. II | Transaction will result in OmniAb becoming an independent publicly-traded company Ligand’s shareholders to receive 100% of Ligand’s shares in OmniAb through a tax-free distribution immediately prior to the merger EMERYVILLE, Calif. & ... |
| 14.12.2021 | Genedata Biologics Selected as Global Antibody Discovery Workflow Platform for Ligand Pharmaceuticals | Genedata Biologics was recommended repeatedly as the industry standard for biopharmaceutical R&D and is the only such software developed specifically for antibodies. BASEL, Switzerland (PRWEB) December 14, 2021 Genedata, the leading pro... |